EMERGENT BIOSOLUTIONS INC. Deferred Revenue
EMERGENT BIOSOLUTIONS INC. (EBS) had Deferred Revenue of $13.23 million as of 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-02-23
- 2017-12-31: Deferred Revenue, Current $13.23M.
- 2017-09-30: Deferred Revenue, Current $4.51M.
- 2017-06-30: Deferred Revenue, Current $15.41M.
- 2017-03-31: Deferred Revenue, Current $10.65M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2017-12-31 | $13.23M 10-K · filed 2018-02-23 | |
| 2017-09-30 | $4.51M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $15.41M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $10.65M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $7.04M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $4.82M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $7.13M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $9.59M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $3.98M 10-K · filed 2017-02-28 | $7.94M 10-K · filed 2016-02-29 |
| 2015-09-30 | $8.73M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $7.34M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $5.27M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $5.34M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $5.81M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $5.33M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $5.18M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $1.83M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $2.04M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $2.05M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $2.01M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $1.81M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $1.57M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $1.50M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $283.00K 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $1.36M 10-K · filed 2013-03-08 | |
| 2011-09-30 | $4.36M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $5.34M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $7.84M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |